ALX Oncology
ALXO
75 hedge funds and large institutions have $258M invested in ALX Oncology in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 26 increasing their positions, 18 reducing their positions, and 22 closing their positions.
759% more call options, than puts
Call options by funds: $739K | Put options by funds: $86K
60% more capital invested
Capital invested by funds: $161M → $258M (+$96.2M)
44% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 18
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3.45% less ownership
Funds ownership: 87.37% → 83.91% (-3.5%)
13% less funds holding
Funds holding: 86 → 75 (-11)
50% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$4.56M |
| 2 |
BlackRock
New York
|
+$786K |
| 3 |
Millennium Management
New York
|
+$465K |
| 4 |
Renaissance Technologies
New York
|
+$366K |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$317K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
-$3.27M |
| 2 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$3.01M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.67M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$1.19M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1M |
ALXO Hedge Fund Activity: Q2 2023 in Review
75 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in ALX Oncology (ALXO) for Q2 2023, worth a combined $258M — up 60% from $161M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of ALXO and 11 opened new positions — a net loss of 11 holders — while 18 trimmed existing stakes and 26 added.
The largest buyer was Redmile Group, adding an estimated $4.56M. The largest seller was Logos Global Management, cutting an estimated $3.27M.
- 75 institutional investors held ALX Oncology (ALXO) as of Q2 2023, down from 86 in Q1 2023.
- Funds reported $258M of ALX Oncology stock for Q2 2023, up 60% quarter-over-quarter.
- 11 funds opened new ALX Oncology positions in Q2 2023 and 22 closed out, a net change of -11 holders.
- The largest ALX Oncology buyer in Q2 2023 was Redmile Group, an estimated $4.56M added.
- The largest ALX Oncology seller in Q2 2023 was Logos Global Management, an estimated $3.27M sold.
Based on aggregated 13F filings for Q2 2023.